<DOC>
	<DOC>NCT01031355</DOC>
	<brief_summary>Investigation of the bioequivalence (BE) of Estradiol Valerate (EV) after administration of one film-coated tablet containing 3 mg Estradiol Valerate and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 3 mg Estradiol Valerate Investigation of the bioequivalence of levomefolate calcium after administration of one film-coated tablet containing 3 mg Estradiol Valerate and 0.451 mg Levomefolate calcium as compared to one film-coated tablet containing 0.451 mg levomefolate calcium</brief_summary>
	<brief_title>Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium</brief_title>
	<detailed_description />
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>BMI:&gt;18 &lt;30 kg/mÂ² Healthy female volunteers Age 4575 years Postmenopausal state Contraindications for use of combined (Estradiol Valerate/dienogest) contraceptive (e.g.history of venous/arterial thromboembolic disease) Regular intake of medication Clinically relevant findings (ECG, blood pressure, physical and gynaecological examination, laboratory examination) Smoking</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Female Contraception</keyword>
	<keyword>Contraceptives, Oral</keyword>
</DOC>